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Summary 
Background: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) 
and Crohn’s disease (CD) is characterized in patients by repeated periods of 
disease activity and remission. In recent years, fecal biomarkers have been 
evaluated for their ability to aid diagnosis of IBD, differentiate IBD from irritable 
bowel syndrome (IBS), assess IBD activity and estimate prognosis. 
Aim: An expert panel met to discuss the development of a rapid point-of-care 
semi-quantitative test for discrimination of IBD from IBS and subsequent disease 
activity monitoring in patients with IBD. 
Methods: Eleven gastroenterologists with expertise in IBS/IBD met in April 2012 
to discuss and agree the most suitable biomarker for a rapid point-of-care 
semi-quantitative test and to recommend the number and cut-off level values in 
various clinical settings. 
Results: Fecal calprotectin was agreed as the most suitable biomarker for the 
point-of-care test. Four clinical situations benefitting from a rapid diagnostic test 
were identified and calprotectin cut-off levels were proposed for each: early 
diagnosis of IBD and discrimination from IBS in primary and/or secondary care 
settings (cut-off level of 100 µg/g), detection and prediction of IBD flares whilst 
in remission (250 µg/g) and monitoring of active IBD to optimize treatment 
(400 µg/g), with 1000 µg/g recommended for diagnosing severe active disease.  
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Conclusion: An expert panel of gastroenterologists recommended four clinical 
settings and corresponding cut-off fecal calprotectin values for the development 
of a rapid point-of-care semi-quantitative test for discrimination of IBD from IBS, 
the detection and prediction of IBD flares during remission and monitoring of 
active and severe active IBD disease.
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Introduction 
Inflammatory bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn’s 
disease (CD) are chronic, organic inflammatory diseases, caused by acute 
mucosal inflammation of the intestine. They are typically characterized by 
variable disease activity, often with repeated periods of intermittent disease 
activity and remission. Irritable bowel syndrome (IBS) is a non-inflammatory 
functional disorder and by definition, presumes the absence of organic disease.1 
As the presenting manifestations of IBD and IBS are similar and can include 
diarrhea, abdominal pain and bloating, obtaining a clinical diagnosis can be 
difficult and further invasive diagnostic procedures may be required in order to 
obtain a confirmed diagnosis.2, 3 
Treatment strategies based on presenting clinical manifestations have failed to 
modify the course of IBD.4, 5 Indeed clinical disease activity indices are 
non-specific and do not correlate with endoscopic activity.2, 5-7  
Mucosal healing has emerged as a new therapeutic goal in clinical practice and is 
regarded as a major endpoint definition for remission of IBD in clinical trials, due 
to its association with improved outcomes in IBD, including reduced relapse and 
hospitalization rates and reduced need for surgery.8 C-reactive protein (CRP) is a 
non-specific marker that reflects systemic inflammation and is useful for the 
detection of complications (such as abscesses) or extraintestinal 
manifestations.9-14 However, it is not an accurate marker of mucosal healing.15 
There is currently an unmet medical need for a suitable non-invasive biomarker 
of mucosal inflammation, arising primarily because of the inherent problems 
associated with endoscopy, which is an invasive and expensive procedure. 
6 
 
Although cross-sectional imaging methods such as MRI16, 17, CT and ultrasound 
are used for assessing disease activity in patients with UC and CD, there is still 
room for the use of fecal markers to evaluate mucosal lesions in clinical practice. 
In addition, a non-invasive test might be used to anticipate flares in IBD activity 
which would allow for pre-emptive escalation of treatment. The ideal marker 
should be specific and sensitive, inexpensive, yield rapid results, which could be 
available during the patient visit, and have a high negative predictive value. 
This article reports the outcomes of a recent meeting of a panel of 
gastroenterologists with expertise in IBD and fecal biomarkers to discuss the 
development of a rapid point-of-care semi-quantitative test to enable 
discrimination of IBD from IBS and subsequent disease activity monitoring in 
patients with IBD. 
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Methods 
In April 2012, 11 gastroenterologists with expertise in IBD and special interest in 
fecal biomarkers met in Zürich, Switzerland to discuss the potential for 
development of a rapid point-of-care, semi-quantitative test. The meeting 
focused on the following main questions:  
1. What is the rationale for choosing fecal calprotectin as the most suitable IBD 
biomarker for the test, compared with other fecal markers such as lactoferrin or 
M2-pyruvate kinase? 
2. What would be the agreed number and cut-off calprotectin level values for 
various clinical settings? 
3. Would it be useful to have different cut-off levels for UC and CD? 
4. Could patients with IBD tailor their treatment to allow earlier escalation of 
their treatments to prevent a relapse of their disease or, alternatively, reduce 
their treatment if their disease was known to be in remission as indicated by the 
results of their fecal marker rapid point-of-care test? 
Finally, the expert panel discussed next steps in terms of a clinical study concept 
to validate agreed consensus calprotectin cut-off levels. 
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Results 
Candidate markers for a rapid point-of-care diagnostic test 
Inflammation of the intestine during the acute-phase IBD is associated with 
migration of leukocytes to the gut, resulting in the production of a large number 
of inflammatory proteins which can be measured in the feces. As a result, several 
leukocyte products and serum proteins have been evaluated for use as fecal 
markers, which can be used to indicate the presence and severity of intestinal 
inflammation.10, 18 Possible fecal markers for IBD include lactoferrin, M2-pyruvate 
kinase, S100A12, calprotectin and polymorphonuclear neutrophil elastase (PMN-
elastase). The characteristics of these IBD markers are summarized in Table 1. 
Lactoferrin is an iron-binding glycoprotein found in neutrophil granulocytes;  its 
levels in feces have been shown to increase quickly following inflammation of the 
intestine.18 Studies have reported that lactoferrin is a sensitive marker of IBD 
activity19-21; however, it is not as widely studied as calprotectin. Walker et al. 
reported promising results from a study of 148 children and young adults with 
IBD (141 with IBD and 7 with IBS, plus 22 healthy controls) in which elevated 
lactoferrin levels were used to identify patients at greater risk of disease 
relapse.22 
M2-pyruvate kinase (M2-PK) is an enzyme involved in glycolysis that is present 
in rapidly dividing cells and has been previously used as a marker of 
gastrointestinal cancers.23 However, its role in gastrointestinal inflammation is 
unknown. A study by Chung-Faye et al. reported elevated concentrations of 
M2-PK in patients with IBD compared with those patients with IBS. However, it 
9 
 
has yet to be shown if M2-PK can be used as a potential marker for predicting 
relapses in asymptomatic patients with IBD.24 
S100A12 (calgranulin C), a member of the human calcium-binding S100 protein 
family, is a cytoplasmic protein found in neutrophils that acts as a marker of 
inflammation.23 Previous studies carried out in both children and adults reported 
positive results regarding the ability of S100A12 to distinguish between IBD and 
IBS.25 However, it has not yet been determined whether S100A12 could be 
useful as a marker of disease relapse in both the pediatric and adult setting.23 
Calprotectin is a heterocomplex of S100A8 (migration inhibitory factor-related 
protein (MRP) 8, calgranulin A) and S100A9 (MRP14, calgranulin B), two other 
members of the calcium-binding S100 protein family.23 Fecal calprotectin 
represents up to 60% of cytosolic protein in neutrophils and levels correlate with 
the influx of neutrophils into the intestine.18 Calprotectin is stable in feces for up 
to 7 days at room temperature and this property offers advantages in both 
clinical practice and in terms of a suitable marker for a diagnostic test.26 
PMN-elastase is a serine proteinase that is secreted by neutrophils and 
macrophages during inflammation and the concentrations of PMN-elastase in 
feces correlate with intestinal inflammation. A study by Schröder et al. identified 
the use of PMN-elastase as a possible tool for the differential diagnosis of IBS; 
however, its diagnostic accuracy is lower than that of lactoferrin and 
calprotectin.27 
The predictive value of biomarkers in the diagnosis and treatment of patients 
with IBD has been more widely explored for calprotectin than the other 
biomarkers mentioned here.23 Of particular interest is the potential for 
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calprotectin levels to be used to diagnose IBD,28 differentiate IBD from IBS,29, 30 
assess IBD activity, and predict relapse of active disease.31-36 Several clinical 
studies have demonstrated that not only does fecal calprotectin significantly 
correlate with endoscopic disease activity in active IBD,15, 28, 37-40 but also that a 
normalization of fecal calprotectin equates to mucosal healing in IBD, which is an 
important treatment target goal.41-45 Studies have shown that fecal calprotectin 
levels more closely correlate with endoscopic disease findings than CRP, blood 
leucocytes, CDEIS and CDAI.15, 38 A report commissioned by the UK Department 
of Health in 2009 found fecal calprotectin to be more cost effective and accurate 
in discriminating between IBS and IBD in primary care in comparison to other 
inflammatory markers of IBD, such as CRP.46 In addition, the UK National 
Institute for Health and Clinical Excellence is currently developing guidance on 
the application of fecal calprotectin as a diagnostic test for the differentiation of 
IBD from IBS.47 Use of fecal calprotectin for diagnosing IBD could lead to a 
reduction in the number of specialist referrals for further invasive endoscopic 
investigations. A meta-analysis of 13 prospective diagnostic accuracy studies  
(6 studies involving 670 adults with fecal calprotectin cut-off levels ranging from 
24 µg/g to 150 µg/g; and 7 studies involving 371 children with fecal calprotectin 
cut-off levels ranging from 32 µg/g to 100 µg/g) predicted that screening with 
fecal calprotectin to exclude IBD could hypothetically reduce the number of 
endoscopy referrals by 67% in adults and by 35% in children.48 
On the basis of the current available evidence, the expert panel agreed that fecal 
calprotectin would be the best potential biomarker for a rapid point-of-care 
diagnostic test. 
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Currently, most assays for fecal calprotectin are based on the enzyme-linked 
immunosorbent assay (ELISA) method, which can be associated with a delay of 
up to 3 weeks before obtaining the results.31 However, the ELISA method 
provides a quantitative result, which might be of additional clinical value. 
Previous studies have shown that there is some variability in calprotectin values 
both between patients and between samples; therefore, the clinical value of 
quantitative data remains to be determined.29, 35, 40, 49 Development of a rapid, 
semi-quantitative, point-of-care test would dramatically reduce the turnaround 
time for test results to be available to physicians, thus allowing for a faster 
decision to be made regarding the current IBD status of a patient and the 
subsequent suitable treatment options. 
An ideal rapid point-of-care diagnostic test needs to be easy to perform, 
accurate, specific and sensitive, and yield rapid results at the point-of-care, to 
allow the test results to be available during the patient visit.  
Use of a semi-quantitative rapid point-of-care calprotectin 
test in clinical settings 
The expert panel reached a consensus that a semi-quantitative fecal calprotectin 
point-of-care test would be useful in several IBD clinical settings: at initial 
diagnosis (discrimination between organic [IBD] and non-organic disease [IBS]); 
monitoring of patients with chronic IBD currently in remission; and monitoring of 
therapy efficacy in patients with active and severe active disease. The expert 
panel also agreed on the number and range of cut-off levels for each setting 
depending on the intended use (Table 2). 
Kommentar [JB1]: Dear authors, 
previous drafts of the manuscriot 
stated that a summary of the 
results reported in three recent 
abstracts comparing the Bühlmann 
and immunodiagnostic ELISA test 
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I have been unable to obtain the 
abstracts from the AGA and UEGW 
meetings (as per Dr Logan’s 
suggestion). 
 
Given the current manuscript word 
count of 3,428, please could you 
advise if this information is 
essential for inclusion in the 
manuscript? 
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Diagnosis of IBD and discrimination from IBS in primary and/or 
secondary care settings 
An important goal of a semi-quantitative point-of-care test would be the 
non-invasive discrimination of IBD from IBS. This point-of-care test would be 
ideally placed for use during the early diagnosis stage in primary care but it could 
also be used in the secondary care setting, as well as for differentiation of 
symptomatic patients with coexisting IBD and IBS. Discriminating possible IBD 
from IBS at an early stage would avoid unnecessary specialist referral of patients 
and subsequent endoscopic investigations. A single cut-off level of 100 µg/g was 
agreed by the expert panel as appropriate for this purpose based on results from 
previous studies which reported increased diagnostic precision for discrimination 
of colorectal inflammation in patients with CD and UC at 100 µg/g.50, 51 This 
agreed cut-off level of 100 µg/g is higher than the levels suggested in recent 
studies, in which cut-off values of 30 to 50 µg/g were recommended.28, 29, 37, 40, 46 
It was agreed at the expert meeting that a higher cut-off level would be desirable 
to maximize the negative predictive value of the test to reduce incorrect 
diagnoses of IBD. As indicated in Table 2, a negative test result at the lowest 
cut-off level suggests a diagnosis of a non-inflammatory condition, such as IBS. 
A positive test result at the cut-off level of 100 µg/g may indicate IBS, with a 
recommendation to repeat the test in 6 weeks to confirm the initial result. 
However, a normal fecal calprotectin level alone would not be sufficient to 
confirm a diagnosis of IBS, without diagnostic criteria, such as Rome III being 
met. Positive results at both the 100 µg/g and 250 µg/g cut-off levels may 
indicate IBD rather than IBS.1  
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Detection and prediction of IBD flares whilst in remission 
Another important clinical setting and goal for development of a 
semi-quantitative test was management of patients with established chronic IBD 
currently in remission. For patients exhibiting mild or moderate IBD symptoms, a 
corresponding increase in fecal calprotectin levels (as indicated by a positive 
point-of-care test result, Table 1) would be used to confirm/predict an active 
flare of IBD and suggest to physicians that a change of treatment or dose 
adjustment is required, without the need for further endoscopic investigations. 
For patients who are well, with minimal or no IBD symptoms, a point-of-care test 
with one or two cut-off values would be used to indicate and confirm that the 
disease is in a period of remission. It was recommended by the expert panel that 
both positive and negative test results should ideally be repeated to confirm the 
test result. 
A fecal calprotectin value of 250 µg/g was deemed appropriate as a cut-off value 
for monitoring IBD remission based on results from previous studies. D’Haens et 
al. reported the results of a study which included 126 patients with IBD  
(87 patients with CD and 39 patients with UC) and proposed a fecal calprotectin 
cut-off value of 250 µg/g for indicating IBD remission.37 An earlier study by 
Sipponen et al., which included 77 patients with CD (106 endoscopies) proposed 
a cut-off value of 200 µg/g for identification of endoscopically inactive disease.38 
In another study of 115 patients with CD, fecal calprotectin levels less than 
300 µg/g were associated with a reduced risk of disease relapse.34 
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Monitoring of active IBD to optimize treatment 
Finally, the use of a point-of-care fecal calprotectin test would help assess 
therapy efficacy and optimize treatment in patients with active and severe active 
IBD by monitoring a reduction in fecal calprotectin levels. Fecal calprotectin 
levels are a sensitive measure of therapeutic efficacy and test results would aid 
physicians with treatment modification decisions. A cut-off calprotectin value of 
400 µg/g was agreed by the expert panel with a further cut-off level of 
1000 µg/g proposed for monitoring therapy efficacy in patients with severe active 
IBD. These two values were selected by the panel based on data from previously 
published studies which report a range of mean and median fecal calprotectin 
values of 175 µg/g,37 465 µg/g,37 718 µg/g,15 810 µg/g52 and 1260 µg/g53 in 
patients with active and severe active UC and CD. 
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Discussion 
Experts agreed that a semi-quantitative fecal calprotectin test will be useful in 
clinical practice settings. The suggested cut-off values agreed by the expert 
panel are intended for a point-of-care test for use initially in patients with UC. It 
remains to be established if these proposed cut-off values can be used for 
patients with CD as the evidence base for interpreting fecal calprotectin results in 
patients with CD is less robust, which is partly due to the greater variety of 
disease manifestations in patients with CD. 
There are some limitations to using fecal calprotectin as a proposed biomarker 
for monitoring disease activity in patients with IBD. Fecal calprotectin is a 
non-specific disease biomarker and whilst it is useful for discriminating IBD 
(organic disease) from IBS (non-organic disease), it is not useful for 
discriminating UC from CD or to discriminate active IBD from infectious 
gastrointestinal disease. Other presenting conditions such as non-steriodal anti-
inflammatory drugs, tumors, and diverticulitis which cause an increase in 
intestinal neutrophils will result in increased concentrations of fecal calprotectin. 
Fecal calprotectin is more sensitive for detection of mild mucosal inflammation 
than CRP. In severely active cases, CRP better reflects systemic inflammation.12, 
14, 29 
Currently available tests can also yield results that vary substantially between 
and within patient samples, particularly in patients with CD.34, 40, 49, 54 Results can 
also vary depending on the mixing, consistency and quantity of the stool sample, 
necessitating a standardized sample collection and preparation method to ensure 
test results are as accurate as possible.55 Due to this variability in test results, 
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individual values can sometimes be difficult to interpret and it may be more 
appropriate to look at gross changes in fecal calprotectin levels i.e., a 
semi-quantitative rather than a quantitative test.  
Semi-quantitative tests are fast, cheap, and may have the potential to be 
performed at home by the patients themselves or in an outpatient setting during 
patient visits. Home-tests are currently being used by patients with UC in Norway 
who are concerned that they may be having a flare.49 An easy-to-use 
semi-quantitative test would offer practical advantages in this setting, enabling 
home-based testing to become more widely used for the monitoring of IBD. This 
would be of particular benefit to patients who are located some distance from 
medical centers or hospitals. It would also provide patients with a higher degree 
of ownership and sense of control over their condition. However, the expert 
panel agreed that both patient education and a good physician-patient 
relationship would be key support requirements needed to ensure correct usage 
and good compliance of a home-based semi-quantitative test, to ensure a benefit 
for patients. As the involvement of General Practitioners (GPs) in the diagnosis 
and treatment of IBD varies greatly between European countries, GPs do not 
always have the opportunity to provide their patients with this necessary 
support. 
The expert panel agreed that a benchmarking study should be undertaken 
comparing the rapid point-of-care test against the standard ELISA test. This 
proof-of-concept study should evaluate the impact of the point-of-care test on 
the doctor’s decision-making process and any potential improvement in patient’s 
health-related quality of life, measured, for example, by reduced hospitalization 
of patients and a reduction in the number of invasive endoscopies. The 
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prognostic value of the point-of-care test should be included as a study endpoint 
measure.  
In addition, larger prospective studies were suggested to be carried out to 
validate the cut-off values in clinical practice in patients with UC, using 
endoscopy as a reference for monitoring intestinal inflammation. Once cut-off 
values have been established for patients with UC, cut-off values for patients 
with CD could then be developed and validated, although cut-off values in CD will 
be harder to establish due to lack of consistent evidence. In addition, small 
intestinal disease is only reflected to a variable extent by fecal calprotectin 
values in contrast to colon involvement.28, 56 At the time of preparing this paper, 
the UK National Institute for Health Research Health Technology Assessment 
Programme is welcoming applications from researchers to develop and validate a 
fecal biomarker tool, which can be used in primary and secondary care, for early 
detection of relapse in patients with CD.57  
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Conclusions 
As a sensitive biomarker of mucosal inflammation, fecal calprotectin could be 
used in a rapid point-of-care test to monitor disease activity in patients with IBD 
and help reduce unnecessary specialist referrals and subsequent endoscopic 
investigations, which can be both uncomfortable and painful for the patient and 
time-consuming and costly for health services. As one of the main limitations of 
current calprotectin tests is the slow turnaround of results, a rapid 
semi-quantitative test would be an important development. This article reports 
the consensus opinion of an expert panelof gastroenterologist with expertise in 
IBD and highlights four clinical situations whereby the use of a rapid 
semi-quantitative test could be helpful, with recommended fecal calprotectin cut-
off values proposed for each situation: early diagnosis and discrimination of IBD 
from other diseases such as IBS in primary and/or secondary care settings  
(cut-off level of 100 µg/g); detection and prediction of IBD flares in patients 
currently in remission (cut-off level of 250 µg/g); monitoring of active IBD 
(cut-off level of 450 µg/g); and severe active IBD (cut-off level of 1000 µg/g) to 
optimize treatment efficacy. Large prospective studies will be required to validate 
the recommended cut-off values in clinical practice. 
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Tables  
Table 1. Characteristics of existing IBD markers 
Criteria for comparison Lactoferrin M2-pyruvate kinase S100A12 Calprotectin PMN-elastase 
Structure Iron-binding glycoprotein Key enzyme in the glycolytic 
pathway 
Cytoplasmic protein Calcium-binding protein, 
heterocomplex of S100A8 and 
S100A9 proteins 
Glycoprotein belonging to the 
group of serine proteinases 
Derived from Secondary granules of 
polymorpho-nuclear neutrophils 
Expressed by proliferating 
tissues 
Neutrophils Mainly from neutrophils, 
occasionally from monocytes 
and reactive macrophages 
Active PMN-elastase released 
from azurophil granula of 
neutrophil granulocytes 
Role in inflammatory 
response 
Primary factor in inflammatory 
response 
Unknown Contributes to processes of 
gut inflammation 
Released from cells during cell 
activation 
Infiltrates the mucosa during 
intestinal inflammation 
Stability in feces Up to 5 days at room 
temperature 
For 2 days at room temperature Up to 7 days at room 
temperature 
Up to 7 days at room 
temperature 
Up to 3 days at 2–8°C 
Diseases in which increased 
levels of markers have been 
reported 
IBD Cancers (including colorectal, 
pancreatic, gastric, renal, lung) 
Inflammatory disorders 
(rheumatoid arthritis and 
cystic fibrosis) 
IBD Inflammatory reactions involving 
neutrophils e.g., chronic joint 
inflammation, bacterial infection 
Role as a marker for 
predicting relapses 
Promising22 Unknown Unknown Potential to predict relapse in 
IBD 
Potential tool for the differential 
diagnosis of IBD27 
Abbreviations: PMN, polymorphonuclear neutrophils. Information derived from: Judd et al. Journal of gastroenterology and hepatology 2011; 26(10):1493–1499 and Schröder 
et al. Alimentary Pharmacology & Therapeutics 2007;26:1035–1042
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Table 2. Proposed interpretation of results of a rapid point-of-care test 
Fecal calprotectin cut-off levels in semi-quantitative test 
100 µg/g 250 µg/g 400 µg/g 1000 µg/g Interpretation 
Patients in primary care with suspected IBS 
NEGATIVE NEGATIVE NEGATIVE NEGATIVE Result confirms IBS* 
POSITIVE NEGATIVE NEGATIVE NEGATIVE Result suggests IBS*, repeat in 6 
weeks to confirm initial result 
POSITIVE POSITIVE NEGATIVE NEGATIVE Result suggests possible IBD, repeat 
in 4 weeks 
POSITIVE POSITIVE POSITIVE NEGATIVE Result consistent with IBD, refer for 
specialist opinion 
POSITIVE POSITIVE POSITIVE POSITIVE Result indicates IBD 
Patients in primary care with established UC 
POSITIVE POSITIVE POSITIVE POSITIVE Result confirms active disease, 
consider changing/escalating 
treatment, consider admitting 
patient to hospital 
POSITIVE POSITIVE POSITIVE NEGATIVE Result suggests flare of IBD, 
consider changing/escalating 
treatment 
POSITIVE POSITIVE NEGATIVE NEGATIVE Result suggests IBD in remission 
POSITIVE NEGATIVE NEGATIVE NEGATIVE Result suggests IBD in remission 
NEGATIVE NEGATIVE NEGATIVE NEGATIVE Result confirms IBD in remission 
IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; UC, ulcerative colitis 
*In conjunction with Rome III criteria for IBS being met  
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